These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 12799792)

  • 41. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 42. Escalating immunotherapy of multiple sclerosis.Austrian-German- Swiss Multiple Sclerosis Therapy Consensus Group [MSTCG].
    Rieckmann P; Toyka KV
    Eur Neurol; 1999; 42(3):121-7. PubMed ID: 10529535
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL; Oger J
    Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Why treat early multiple sclerosis patients?
    Comi G
    Curr Opin Neurol; 2000 Jun; 13(3):235-40. PubMed ID: 10871245
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glatiramer and suspected multiple sclerosis. No proven advantage.
    Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
    [No Abstract]   [Full Text] [Related]  

  • 47. Confusion over UK beta-interferon "trials".
    Dean M
    Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
    [No Abstract]   [Full Text] [Related]  

  • 48. Immunologic therapy for secondary and primary progressive multiple sclerosis.
    Myers LW
    Curr Neurol Neurosci Rep; 2001 May; 1(3):286-93. PubMed ID: 11898531
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Multiple sclerosis].
    Itoyama Y
    No To Shinkei; 2000 Dec; 52(12):1051-5. PubMed ID: 11193536
    [No Abstract]   [Full Text] [Related]  

  • 51. Comparative studies of glatiramer acetate and interferon beta.
    Goodin D
    Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Update on MS treatment.
    Ryan M
    J Am Pharm Assoc (Wash); 1996 Jul; NS36(7):419-20. PubMed ID: 8840740
    [No Abstract]   [Full Text] [Related]  

  • 53. The treatment of multiple sclerosis: current and future.
    Polman CH; Hartung HP
    Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical surveillance of patients with multiple sclerosis].
    Cazzato G; Zorzon M
    Recenti Prog Med; 2003 Apr; 94(4):173-6. PubMed ID: 12677789
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [New therapeutic methods in the treatment of multiple sclerosis].
    Nervenarzt; 1996 Nov; 67(11 Suppl Neue Ther):1-12. PubMed ID: 9402424
    [No Abstract]   [Full Text] [Related]  

  • 56. Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis.
    Lana-Peixoto MA; Teixeira AL; Haase VG
    Arq Neuropsiquiatr; 2002 Sep; 60(3-B):721-4. PubMed ID: 12364937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. International consensus statement on the use of disease-modifying agents in multiple sclerosis.
    Freedman MS; Blumhardt LD; Brochet B; Comi G; Noseworthy JH; Sandberg-Wollheim M; Soelberg SP;
    Mult Scler; 2002 Feb; 8(1):19-23. PubMed ID: 11936483
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Disease-modifying treatments in multiple sclerosis].
    Confavreux C; Bouhour F; Vukusic S
    Rev Prat; 1999 Nov; 49(17):1882-9. PubMed ID: 10598505
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Key issues in the diagnosis and treatment of multiple sclerosis. An overview.
    O'Connor P;
    Neurology; 2002 Sep; 59(6 Suppl 3):S1-33. PubMed ID: 12448786
    [No Abstract]   [Full Text] [Related]  

  • 60. Treatment of cognitive impairment in multiple sclerosis.
    Pierson SH; Griffith N
    Behav Neurol; 2006; 17(1):53-67. PubMed ID: 16720960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.